TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Propaten Randomized Investigation on Cost-benefit and Efficacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥18 years of all ethnicities~* End-stage Renal Disease stage 4 (GFR 15-29 ml/min 1.73m2) or stage 5 (GFR \<15ml/min 1.73m2) per National Kidney Foundation guidelines~* Currently undergoing hemodialysis with a failure of previous access~* Expected to undergo hemodialysis within 6 months of presentation~Exclusion Criteria:~* Unable/refuse to abide with follow-up~* Known hypercoagulability syndrome or a bleeding disorder~* On a previous anticoagulant treatment~* Intraoperative decision in favor of fistula instead of graft~* Pregnant or breast-feeding women~* A documented history of heparin induced thrombocytopenia or allergy~* Active infections~* Evidence or suspicion of central vein stenosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PROPATEN (Type: EXPERIMENTAL): patients with heparin-bonded graft implantation
- Standard Graft (Type: ACTIVE_COMPARATOR): patients undergoing ePTFE hemodialysis graft implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Protected Versus Early Weight Bearing Post Microfracture Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 16-60 years. Mechanically stable knee joint at outpatient examination. MRI confirmed grade 3 or 4 non-kissing cartilage defect within the knee. Able to fully understand the process and study and give informed consent to participate.~Able to comply with the physiotherapy rehabilitation and follow up process.~Exclusion Criteria:~* Kissing cartilage defects. Defects deemed too large to undergo microfracture on MRI scan. Clinically unstable knee joint. Patients unable to consent to participation. Under 16 years of age or over 60 years of age. Patients likely to drop out of physiotherapy rehabilitation and study follow up.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- early weight bearing (Type: ACTIVE_COMPARATOR): early weight bearing and accelerated physiotherapy rehabilitation
- protected weight bearing (Type: ACTIVE_COMPARATOR): protected weight bearing and conservative physiotherapy rehabilitation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological documented diagnosis of inoperable, locally advanced, recurrent or metastatic (Stage IIIB or Stage IV) NSCLC.~* Chemo-naïve patients.~* Patients who are in the investigator's opinion not medically suitable for chemotherapy.~* Measurable disease according to the RECIST criteria.~* ECOG performance status of 0 - 3.~* Life expectancy of at least 12 weeks.~* Patients must be able to take oral medication.~* Serum calcium within normal ranges~* ≥ 4 weeks since prior surgery or radiation therapy~* For all females of childbearing potential a negative pregnancy test must be obtained within 48 hours before starting therapy and must use effective contraception~* 18 years of age or older~* Written (signed) Informed Consent to participate in the study~Exclusion Criteria:~* Prior systemic antitumor therapy~* Any unstable systemic disease which according to the investigator contraindicates the use of the study drug render the subject at high risk from treatment complications (including active infection, unstable angina, myocardial infarction within the previous month, inflammatory bowel disease, hepatic disease with serum bilirubin ≥ 2 upper limit of normal (ULN) or AST and/or ALT ≥ 2 x ULN (or ≥ 5 x ULN if clearly attributable to liver metastasis), renal disease with acute renal failure or serum creatinine ≥ 5 x ULN.~* Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).~* Nursing mothers or pregnant woman.~* Hypersensitivity to Tarceva or co-formulants.~* Patients with brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation.~* Patients with brain metastasis or spinal cord compression that not are in a stable condition despite treatment with steroids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- arm 1 medicine (Type: EXPERIMENTAL): erlotinib daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Custom-manufactured vs. Off-the-rack (OTR) Compression Hosiery for Initial Management of Venous Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to comprehend and sign an informed consent and complete study questionnaires~* Patient is participating in usual work and home activities with no changes anticipated for the duration of the study~* The use of compression stocking is prescribed in accordance with the usual practice and management of venous disorders~* The patient will confirm they are willing to pay for the compression stockings.~Exclusion Criteria:~* The patient has a known allergy to any component of the stocking (latex, etc)~* The patient has non-venous source of pain in either leg that could, in the opinion of the investigator, confound the results of the study i.e.Neuropathy, Arterial insufficiency, Diabetes~* The patient is confined to bed~* The patient has uncontrolled Congestive Heart Failure~* The patient has acute dermatitis~* The patient has weeping dermatosis~* Patients with venous ulcers will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Custom-manufactured compression hosiery (Isobar) (Type: EXPERIMENTAL): The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
- Off-the-rack stockings (Sigvaris) (Type: ACTIVE_COMPARATOR): Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing of the Gastrointestinal Motility in Irritable Bowel Syndrome (IBS) Patients With Healthy Volunteers

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged over 18.~* Patients who are diagnosed with IBS according to the Rome III criteria.~* A total symptom score in GSRS-IBS at a minimum of 40 points.~* Patients who are psychologically stable and suitable for observation and able to provide informed consent.~Exclusion Criteria:~* Overt bowel diseases including inflammatory bowel disease.~* Pregnant or breast feeding.~* Patients who are considered unable to follow the planned programme of the study, including mental illness or physiological instability.~* Patients who are on medication with known influence on gastrointestinal motility including those for thyroid disease, diabetes mellitus, celiac disease and neurological disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IBS-D (Type: None): 12 IBS-D patients who will all undergo MTS.
- IBS-C (Type: None): 12 IBS-C patients who will all undergo MTS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~For Patients:~* Aged ≥ 18 and ≤ 70 years~* Men or women~* With multiple sclerosis since 2 and 25 years~* Affiliates or beneficiaries of social security scheme~* Signed consent~For Healthy volunteers:~* Aged ≥ 18 and ≤ 70 years~* Men or women~* Matched in accordance with age, sex and level of physical activity~Exclusion Criteria:~For Patients and Healthy volunteers:~* High heart rate resting~* Blood pressure \> 144/94 mmHg~* Recent adjustment of drug or drug can have an impact on fatigue or stimulant for fatigue~* Taking neuroactive substances that can alter corticospinal excitability~* Contraindication at application magnetic field~* Contraindication at Magnetic Resonance Imaging (MRI)~* Currently participating in a structured exercise program~* Pregnant~For Patients only:~* Spasticity or cerebellar ataxia~* Abnormal range of motion (toe and/or ankle)~* Musculoskeletal injuries that impedes pedaling~* Appearance of symptoms of multiple sclerosis in the 90 days preceding the study~For Healthy volunteers:~- Neurological diseases, cardiovascular, musculoskeletal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Patient with multiple sclerosis and lowly fatigued (Type: EXPERIMENTAL): Patient with multiple sclerosis and lowly fatigued will be included.~They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue
- Patient with multiple sclerosis and highly fatigued (Type: EXPERIMENTAL): Patient with multiple sclerosis and highly fatigued will be included. They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue
- Healthy subjects (Type: ACTIVE_COMPARATOR): Healthy subjects will be included. They will have:~Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~(1) Obese (BMI≥30 kg/m2) women with PCOS between 18-40 years of age: i) oligomenorrhea (8 menstrual periods annually), ii) biochemical hyperandrogenemia (elevated total or free testosterone), iii) normal thyroid function tests and serum prolactin, and iv) exclusion of 21α-hydroxylase deficiency by a fasting 17α-hydroxyprogesterone \<200 ng/dl.48, (2) acceptable health on the basis of interview, medical history, physical examination, and laboratory tests (complete blood chemistry (CBC), complete metabolic panel (CMP), urinalysis, serum Beta-Human Chorionic Gonadotropin (BhCG)). (3) Signed, witnessed informed consent. (4) Ability to comply with study requirements.~Exclusion Criteria:~(1) Diabetes mellitus by fasting glucose or oral glucose tolerance test (OGTT), or clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, neoplastic and malignant disease (other than non-melanoma skin cancer). (2) Current use of oral contraceptives. (3) Documented or suspected recent (within one year) history of drug abuse or alcoholism. (4) Ingestion of any investigational drug within two months prior to study onset.~-

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Flutamide
- 2 (Type: PLACEBO_COMPARATOR): control to arm 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: InSpace™ System in Comparison to Best Repair of Massive Rotator Cuff Tear.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Age 40 or older.~* Positive diagnostic imaging (CT arthrogram or MRI)\* of the affected shoulder indicating full thickness Massive RCT of at least 5cm in diameter (according to Cofield classification) or long - narrow tears of at least 4cm2 (W\>2cm and L\>2cm) including fatty infiltration grade III or IV (according to classification of Goutallier) involving more than one tendon. - Persistent pain and functional disability of the affected shoulder for at least 3 months.~Main Exclusion Criteria :~* Known allergy to the balloon material (copolymer of PLA and -θ-caprolactone).~* Evidence of significant osteoarthritis or cartilage damage in the shoulder~* Evidence of gleno-humeral instability~* Previous surgery of the shoulder in the past 2 years, excluding diagnostic arthroscopy~* Evidence of major joint trauma, infection, or necrosis in the shoulder~* Partial-thickness tears of the rotator cuff

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Best Repair of torn Rotator Cuff (Type: SHAM_COMPARATOR): Subjects will undergo surgical intervention (usually arthroscopy) to perform debridment, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
- InSpace™ system (Type: ACTIVE_COMPARATOR): Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridment, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients infected with VIH-1, documented with a positive HIV-1 antibody test and/or positive PCR, confirmed for HIV-1 RNA.~* Patients treated with a HAART that should contain AZT+3TC+ABC (Trizivir®)~* Patients with an indetectable viral load, which will be defined \<40 copies/mL within the last six months.~* Patients with a lipoatrophy clinical evidence (which will be defined as moderate or severe, according to the Lipodystrophy Severity Grading Scale).~* Men or women aged ≥ 18.~* For women of childbearing potential, negative urine pregnancy test during the Screening visit.~* Patients that have signed and dated the Informed consent Form prior to any Study-specific procedure.~Exclusion Criteria:~* Patients with evidence of protease inhibitors failure, and/or documented evidence of protease gene resistance mutation. This evidence could be prior or during the inclusion period in the Study.~* Patients who, for any reason could not be treated with LPV/r.~* Cachexia, defined as an Body Mass Index \<17 Kg/m2.~* Pregnant or breastfeeding women, or women of childbearing potential who do not use the appropriate contraceptive method, according to the Investigator judgment.~* Clinically relevant disease or condition, according to the Investigator judgment, three months prior to the patient inclusion in the Study.~* Patients taking the following concomitant medication that could affect the adipocyte function or morphology, such as: insulin, steroids, anabolic steroid, anti-inflammatory medication for more than three months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Kaletra, all patients (Type: EXPERIMENTAL): Patients will change actual treament for monotherapy LPV/r. They only will take Kaletra 2/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-90 years ;~2. COVID-19 confirmed case ;~3. Cases showing respiratory symptoms, checking at least one of the following criteria:~   1. Cough, dyspnea, respiratory rate \> 24 breaths/min~  2. Oxygen saturation \< 95% at rest in ambient air~  3. PaO2 \< 70mmHg~  4. Scanographic pulmonary compatible with COVID in the absence of any other etiology~4. Risk of deterioration, checking at least one of the following comorbidity criteria :~   1. Chronic respiratory pathology~  2. Diabetes~  3. Cancer pathology~  4. Cardiovascular disease~  5. Chronic kidney failure~  6. Congenital or acquired immunodeficiency~  7. Cirrhosis at stage B~  8. Major sickle cell syndrome~  9. BMI \> 30 kg/m2~OR one of the biological criteria :~1. D-dimer 1 µg/mL,~2. Lymphocytes \< 0.8 G/L,~3. Ferritin \> 300 µg/L,~4. Troponin I \> 11 pg/mL or Troponin T \> 24.8 pg/mL~Exclusion Criteria:~* Patients admitted in intensive care within the first 6 hours of hospital care,~* Patients after 10 days from the start of symptoms~* Age \< 18 years and \> 90 years~* Long-term oxygen-dependent patients (at home),~* Decompensated chronic cardiac, respiratory, urological pathology~* Patient refusing administration of blood products,~* Allergic reaction to plasma products,~* IgA deficiency,~* Contraindication to transfusion~* Ig transfusion within 30 days,~* Patient currently participating to another clinical trial,~* Pregnant women,~* No affiliated to the social security,~* Person deprived of liberty by a legal or administrative decision, person under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- SARS-CoV-2 patients treated with convalescent plasma (Type: EXPERIMENTAL): Subjects will receive an intravenous injection of SARS-CoV-2 Convalescent Plasma.
- SARS-CoV-2 patients treated with standard plasma (Type: ACTIVE_COMPARATOR): Subjects will receive an intravenous injection of standard Plasma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* subject is undergoing resection of pancreas for pancreatic ductal adenocarcinoma (PDAC)~* subject must have adequate renal function~* ECOG performance status of 0-2~* women of child-bearing age and men must agree to use contraception prior to and during the study~Exclusion Criteria:~* subjects receiving any other investigational agents~* significant history of uncontrolled cardiac disease or central nervous system (CNS) disease~* pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTP-01 (Type: EXPERIMENTAL): single IV bolus dose 24 hours prior to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy